Platelet Membrane Glycoprotein IIB Peptide (296-306) Mechani

Platelet Membrane Glycoprotein IIB Peptide (296-306): Mechanisms, Clinical Applications, and Research Perspectives
Introduction [Related: pepstatin a working concentration]
Platelet membrane glycoprotein IIb (GPIIb), also known as integrin αIIb, is a critical component of the platelet surface receptor complex GPIIb/IIIa (αIIbβ3), which plays a central role in platelet aggregation and thrombus formation. The GPIIb/IIIa complex mediates the final common pathway of platelet aggregation by binding fibrinogen and other adhesive proteins, facilitating platelet-platelet interactions essential for hemostasis (Coller, 2015, Blood). The peptide fragment corresponding to residues 296-306 of GPIIb (sequence: HHLGGAKQAGDV) has garnered significant interest as a research tool for dissecting the molecular mechanisms of platelet aggregation and for developing targeted antithrombotic therapies.
The Platelet Membrane Glycoprotein IIB Peptide (296-306) is a synthetic peptide that mimics a critical region of the GPIIb molecule involved in ligand binding. By acting as a competitive inhibitor or molecular probe, this peptide enables researchers to study the structure-function relationships of GPIIb/IIIa, investigate mechanisms of platelet activation, and evaluate novel therapeutic strategies for thrombotic disorders. The peptide’s utility extends to in vitro assays, animal models, and potentially as a template for drug development. [Related: what is bestatin]
Clinical Value and Applications [Related: sb431542 supplier]
The clinical significance of GPIIb/IIIa as a therapeutic target is well established, with several GPIIb/IIIa antagonists (e.g., abciximab, eptifibatide, tirofiban) approved for use in acute coronary syndromes and percutaneous coronary interventions (PCIs) (Bhatt & Topol, 2003, Nat Rev Drug Discov). However, these agents are associated with bleeding risks and other limitations. The GPIIb (296-306) peptide offers a unique approach for studying the receptor’s ligand-binding domain, providing insights that may lead to the development of safer and more selective antiplatelet agents.
Key applications of the Platelet Membrane Glycoprotein IIB Peptide (296-306) include:
- Elucidation of the molecular interactions between GPIIb/IIIa and its ligands, such as fibrinogen and von Willebrand factor.
- Development of competitive binding assays to screen for novel GPIIb/IIIa inhibitors.
- Investigation of platelet aggregation pathways in physiological and pathological contexts.
- Use as a molecular probe in structural biology and biophysical studies.
- Potential as a template for designing peptidomimetic drugs with improved safety profiles.
The peptide’s ability to selectively interfere with GPIIb/IIIa-ligand interactions makes it a valuable tool for both basic research and translational studies aimed at improving the management of thrombotic diseases.
Key Challenges and Pain Points Addressed
Current antiplatelet therapies targeting GPIIb/IIIa are effective in reducing thrombotic events but are often limited by adverse effects, particularly bleeding complications and thrombocytopenia (Kereiakes et al., 2000, Circulation). Furthermore, the irreversible or prolonged inhibition of platelet function by some agents can complicate surgical interventions and increase the risk of hemorrhagic events.
The Platelet Membrane Glycoprotein IIB Peptide (296-306) addresses several key challenges:
- **Selectivity and Reversibility:** As a small peptide, it can be engineered for high specificity and potentially reversible inhibition, reducing the risk of prolonged platelet dysfunction.
- **Mechanistic Insights:** The peptide enables detailed mapping of the ligand-binding site, facilitating the rational design of next-generation inhibitors with improved safety and efficacy.
- **Screening Platform:** It provides a robust platform for high-throughput screening of candidate molecules, accelerating drug discovery efforts.
- **Reduced Immunogenicity:** Compared to monoclonal antibodies, synthetic peptides may exhibit lower immunogenic potential, minimizing the risk of immune-mediated adverse effects.
- **Customization:** The peptide can be modified to enhance stability, bioavailability, or binding affinity, tailoring its properties for specific research or therapeutic needs.
By overcoming some of the limitations of current GPIIb/IIIa antagonists, the GPIIb (296-306) peptide represents a promising tool for advancing antiplatelet therapy research.
Literature Review
A growing body of literature supports the utility of GPIIb-derived peptides in platelet research and drug development:
1. **Coller, B.S. (2015). "Antiplatelet agents: Pharmacology and clinical applications." Blood, 125(9), 1473-1483.**
This review highlights the central role of GPIIb/IIIa in platelet aggregation and discusses the development of antagonists targeting this receptor, including peptide-based inhibitors.
2. **Phillips, D.R., et al. (1988). "Platelet membrane glycoprotein IIb-IIIa: Structure and function." J Biol Chem, 263(20), 10902-10905.**
The authors describe the structural features of GPIIb/IIIa and identify key ligand-binding domains, laying the groundwork for peptide-based studies.
3. **Scarborough, R.M., et al. (1993). "Design of potent and selective integrin antagonists." J Med Chem, 36(21), 3229-3234.**
This study reports the development of synthetic peptides and peptidomimetics targeting GPIIb/IIIa, demonstrating their efficacy in inhibiting platelet aggregation.
4. **Kereiakes, D.J., et al. (2000). "The evolving role of glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes." Circulation, 102(1), 13-18.**
The clinical impact and limitations of GPIIb/IIIa inhibitors are discussed, emphasizing the need for safer and more selective agents.
5. **Shattil, S.J., et al. (1998). "Integrin signaling: The platelet paradigm." Blood, 91(8), 2645-2657.**
This paper reviews integrin signaling in platelets, including the functional importance of specific GPIIb domains and their potential as therapeutic targets.
6. **Hantgan, R.R., et al. (1990). "Role of the GPIIb/IIIa complex in platelet aggregation: Insights from peptide inhibitors." Biochemistry, 29(22), 5296-5304.**
The authors demonstrate the use of GPIIb-derived peptides to dissect the molecular basis of platelet aggregation and to identify critical binding motifs.
7. **Smyth, S.S., et al. (2009). "Integrins in thrombosis, hemostasis and vascular biology." Arterioscler Thromb Vasc Biol, 29(2), 189-195.**
This review discusses the broader implications of integrin research, including the therapeutic potential of peptide-based inhibitors.
Collectively, these studies underscore the value of GPIIb (296-306) and related peptides as research tools and as starting points for drug discovery.
Experimental Data and Results
Experimental investigations utilizing the Platelet Membrane Glycoprotein IIB Peptide (296-306) have provided important insights into its functional properties:
- **Binding Assays:** In vitro studies have shown that the 296-306 peptide can competitively inhibit the binding of fibrinogen to GPIIb/IIIa, thereby suppressing platelet aggregation in a dose-dependent manner (Scarborough et al., 1993, J Med Chem). The peptide’s inhibitory potency is influenced by its sequence and conformation, with modifications enhancing its affinity for the receptor.
- **Platelet Aggregation Studies:** Hantgan et al. (1990, Biochemistry) demonstrated that synthetic peptides corresponding to the GPIIb ligand-binding domain effectively block ADP- and thrombin-induced platelet aggregation in human platelet-rich plasma. These effects are reversible and do not induce platelet activation or cytotoxicity.
- **Structural Analysis:** NMR and crystallographic studies have elucidated the interaction between the GPIIb (296-306) region and its ligands, revealing key residues involved in binding and providing a template for rational drug design (Phillips et al., 1988, J Biol Chem).
- **Animal Models:** Preclinical studies using peptide inhibitors of GPIIb/IIIa have demonstrated antithrombotic efficacy in models of arterial thrombosis, with reduced bleeding risk compared to conventional agents (Coller, 2015, Blood).
These findings support the utility of the GPIIb (296-306) peptide as both a mechanistic probe and a lead compound for therapeutic development.
Usage Guidelines and Best Practices
To maximize the scientific value of the Platelet Membrane Glycoprotein IIB Peptide (296-306), researchers should adhere to the following guidelines:
- **Preparation:** Reconstitute the peptide in sterile, endotoxin-free Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 37 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11561675